Drug Discovery
By
Why Could Novartis’ Ianalumab, With Dual Mechanism of B-Cell Depletion and BAFF-R Inhibition, Revolutionize Treatment for Sjögren’s Disease?
Key Highlights: Positive Phase III Results Confirm Efficacy in Sjögren’s DiseaseThe NEPTUNUS-1 (275 patients) and NEPTUNUS-2 (504 patients)…
Can AstraZeneca’s $50 Billion U.S. Investment and Drug Price Cuts Signal a New Era of Affordable Innovation and Domestic Manufacturing?
Key Highlights: Strategic Response to U.S. Pricing PressuresAstraZeneca CEO Pascal Soriot announced proactive proposals for U.S. drug price…
Can XtalPi & DoveTree’s $6 Billion AI Partnership Transform “Undruggable” Disease Targets in Biopharma – The Dawn of Robotics-Driven R&D at Scale?
Key Highlights: Strategic Overview: Industry’s Largest AI-Pharma CollaborationThis collaboration—one of the biggest in AI-driven drug discovery—combines XtalPi’s robust…
How Will BioNTech’s Patent Settlement Impact the Future of mRNA COVID-19 and Influenza Vaccines Globally?
Key Highlights Resolving Patent Litigation and Securing LicensesBioNTech SE and Pfizer reached agreements with CureVac N.V. and GlaxoSmithKline…
Could Servier’s $450M Fragile X Acquisition Redefine Its Neurology Strategy?
Key Highlights Strategic Fit for ServierThis marks Servier’s first neurology asset acquisition, aligned with its 2030 strategy to…
Could Takeda’s Landmark Phase 3 Oveporexton Results Redefine the Standard of Care in Narcolepsy Type 1?
Key Highlights Clinical Breakthroughs Across EndpointsPatients treated with oveporexton demonstrated marked improvements in excessive daytime sleepiness, with most…
